bluuebunny/crossref_metadata_2025_split huggingface dataset:
Advanced Catalysts for the Chemical Recycling of Plastic Waste
Authors: Qin Jibo , Wu Feiyan , Dou Yibo , Zhao Dan , Hélix‐Nielsen Claus , Zhang Wenjing 
Published: January 2025

AbstractPlastic products bring convenience to various aspects of the daily lives due to their lightweight, durability and versatility, but the massive accumulation of post‐consumer plastic waste is posing significant environmental challenges. Catalytic methods can effectively convert plastic waste into value‐added feedstocks, with catalysts playing an important role in regulating the yield and selectivity of products. This review explores the latest advancements in advanced catalysts applied in thermal catalysis, microwave‐assisted catalysis, photocatalysis, electrocatalysis, and enzymatic catalysis reaction systems for the chemical recycling of plastic waste into valuable feedstocks. Specifically, the pathways and mechanisms involved in the plastics recycling process are analyzed and presented, and the strengths and weaknesses of various catalysts employed across different reaction systems are described. In addition, the structure‐function relationship of these catalysts is discussed. Herein, it is provided insights into the design of novel catalysts applied for the chemical recycling of plastic waste and outline challenges and future opportunities in terms of developing advanced catalysts to tackle the “white pollution” crisis.
Label‐Free Impedimetric Determination of Cortisol Using Gold Nanoparticles Functionalized Laser‐Induced Graphene Interdigitated Electrodes
Authors: Duke Kyle , Dhungana Prakriti , Richards Collin , Preusser Kyle , Romeo Anthony , Gonzalez‐Garcia Jose , Mummareddy Bhargavi , Cortes Pedro , Li Frank , Park Byung‐Wook 
Published: January 2025

AbstractA gold nanoparticle (AuNP) functionalized laser‐induced graphene interdigitated electrode (LIG‐IDE) is fabricated for the label‐free detection of cortisol. Self‐assembled monolayers of 3‐Mercaptopropionic acid immobilized on the AuNP functionalized LIG‐IDE are activated via carbodiimide chemistry for the binding of the anti‐cortisol antibody. The resulting immunosensor is tested for the specific detection of cortisol over the physiologic range (0.1 pm–100 nm) in synthetic human sweat. Electrochemical impedance spectroscopy is used to measure the change in impedance due to cortisol bonding to the LIG surface. The sensor exhibits a good linear (log(concentration)) fit over the entire concentration range (R2 = 0.9662) and a LOD of 0.0085 nm. The minimal effect of synethtic sweat shows its potential use in real‐world applications. A specificity test against similarly structured molecules demonstrates high affinity toward cortisol. Furthermore, the developed sensor exhibits excellent reproducibility with a 5.93%RSD. Given the simple and facile processability of immunosensors, the developed label‐free AuNP functionalized LIG‐based biosensing platform shows great promise as an effective and low‐cost tool suitable for healthcare monitoring and point‐of‐care diagnostics, and it can be applied as an immunosensor for other affinity‐based biosensors.
Cascaded Energy and Charge Transfer Synergistically Prompting 18.7% Efficiency of Layered Organic Solar Cells with 1.48 eV Bandgap
Authors: Zhang Lu , Zhou Hang , Xie Yongchao , Xu Wenjing , Tian Hongyue , Zhao Xingchao , Ni Yuheng , Jeong Sang Young , Zou Ye , Zhu Xixiang , Ma Xiaoling , Woo Han Young , Zhang Fujun 
Published: January 2025

AbstractSeries of layer‐by‐layer organic solar cells (LOSCs) are constructed by sequentially spin‐coating donor layer and acceptor layers. A champion power conversion efficiency (PCE) of 18.79% is achieved from the LOSCs with PBQx‐TCl/ITIC/PY‐DT as active layers, which should be one of the top values among the OSCs with optical bandgap over 1.48 eV. The middle bandgap material ITIC has a complementary photon harvesting range with PBQx‐TCl and PY‐DT, leading to the enhanced photon harvesting of active layers. Meanwhile, ITIC can play a vital role in energy and charge transfer relay to increase exciton utilization and charge transport, which can be confirmed from the varied FFs of normal or inverted LOSCs with ITIC/PY‐DT or PY‐DT/ITIC as acceptor layers. Over 7% PCE improvement of LOSCs can be achieved by employing ITIC as the middle layer to form cascaded energy and charge transfer in the active layers. This work may provide an efficient strategy for improving the performance of LOSCs.
Achieving 20% Efficiency in Organic Solar Cells Through Conformationally Locked Solid Additives
Authors: Wang Siying , Wang Sixuan , Wang Jiarui , Yu Na , Qiao Jiawei , Xie Xianqiang , Li Congqi , Abbasi Misbah Sehar , Ding Ruxue , Zhang Xin , Han Yinghui , Lu Guanghao , Zhang Jianqi , Hao Xiaotao , Tang Zheng , Cai Yunhao , Huang Hui 
Published: January 2025

AbstractVolatile solid additives (VSAs) have emerged as one of the most effective strategies for optimizing the active layer morphology of organic solar cells (OSCs). In this study, two VSAs, HBT‐1 and HBT‐2, are designed and synthesized to investigate the effect of the VASs’ conformation on the photovoltaic performances. Compared to HBT‐1, HBT‐2 incorporates internal noncovalent conformational locks (NoCLs), resulting in reduced conformational disorder, improved molecular planarity, and enhanced crystallinity. These features significantly influence the intermolecular packing of both donor and acceptor materials in the active layer, which can facilitate charge transport and reduce charge recombination. Consequently, the D18:L8‐BO:PY‐C11 OSCs utilizing the HBT‐2 additive achieved an impressive efficiency of 20.01%, markedly higher than devices fabricated without additives (17.83%) and those processed with HBT‐1 (18.76%). Furthermore, HBT‐2 demonstrated excellent compatibility across multiple systems. This work underscores the NoCL strategy as a straightforward and effective approach for designing VSAs for high performance OSCs.
Electrolyte Design Strategies to Construct Stable Cathode‐Electrolyte Interphases for High‐Voltage Sodium‐Ion Batteries
Authors: Xie Kunchen , Ji Yuchen , Yang Luyi , Pan Feng 
Published: January 2025

AbstractElevating the working voltage of sodium‐ion batteries is crucial for expanding their application scenarios. However, as the operating voltage of these batteries increases, the interfacial stability of existing electrolytes becomes inadequate to meet the demands of high‐voltage cathode materials. Along with the interaction with cathode interface, electrolyte trends to be decomposed forming an interphase between the cathode and electrolyte, which plays an essential role in the performance of batteries. This review systematically focuses on the reconstruction of cathode‐electrolyte interphase maintaining the interfacial stability via various strategies at high voltage range. The state‐of‐the‐art characterization techniques and modeling approaches associated with cathode‐electrolyte interphase are also discussed. From the perspective of electrolyte design, the interphase reconstruction strategies focus on solvent molecule manipulation, solute ion manipulation, and the regulation of solvation‐ion interaction. By summarizing strategies for constructing a stable CEI on the cathode, this review aims to provide new insights into achieving high‐voltage sodium‐ion batteries.
Epigenomics dysregulation and therapeutics in neurodegeneration
Authors: Boutillier Anne‐Laurence 
Published: January 2025

AbstractBackgroundAging is the main risk factor of cognitive neurodegenerative diseases such as Alzheimer’s disease, with epigenome alterations as a contributing factor, however, it is not clear which biological mechanisms are common or disease‐specific. Here we investigated epigenomic/genomic signatures in the hippocampus of mouse models of aging and of tauopathy, an AD‐related feature.MethodsAging was modelled by comparing 18‐month‐ versus 3‐month‐old WT mice. Tauopathy was modelled using 12‐month‐old THY‐Tau22 mice. We used high resolution techniques interrogating the whole genome (e.g. high‐throughput sequencing such as Chromatin immunoprecipitation (ChIP) coupled to sequencing, combined with transcriptomics (RNA‐seq), on bulk tissues and at the cellular resolution (FANS‐sorted neuronal nuclei).ResultsAt the transcriptional level, expression of nearly all cholesterol biosynthesis genes was severely impaired in tauopathic mice compared to the model of physiological aging. At the epigenomic level, tauopathy induced hyperacetylation of histone H3 at lysine 27, a marker of active transcription, at neuronal enhancers mostly associated with excitatory neurons. The opposite was found in the aged hippocampus, suggesting that tauopathy is not an exacerbation of an epigenetic drift observed during the aging process. Furthermore, we show that cholesterogenic genes were highly expressed in WT and down‐regulated by tauopathy in CA hippocampal neurons, pointing to a specific vulnerability of these neurons to tauopathy. Lastly, a treatment of tau mice with CSP‐TTK21, a CBP/p300 HAT activator, restored expression of main cholesterol biosynthesis genes, and also unexpectedly counteracted hyperacetylation at neuronal enhancers. This treatment ultimately restored object memory.ConclusionsOur results indicate a link between decreased cholesterol biosynthesis pathway and hyperacetylation in tauopathy, likely through the availability of their common primary substrate, acetyl‐CoA. This work supports the use of molecules capable of activating the cholesterol/mevalonate pathway in the brain subjected to Tau‐related neurodegenerative cognitive diseases (including Alzheimer’s disease) and opens to the use of new epi‐drugs. We are now studying these regulations in response to environmental cues, such as social and physical enrichment, which are emerging as powerful modifiers of disease progression in many neurodegenerative diseases, although their ability to alter the epigenomic landscape of the brain remains poorly described.
Platelet‐based therapies in neurodegeneration: Unlocking blood‐brain crosstalk
Authors: Burnouf Thierry 
Published: January 2025

AbstractUnderstanding the physiological connection between platelets and brain function reveals new paradigms in neurodegenerative disease treatment. Platelets, traditionally associated with hemostasis, but also sometimes regarded as a mirror of neurons in the blood circulation, also encompass a spectrum of neurobiological roles, including neuroinflammation modulation, neurogenesis, and synaptic remodeling. These roles are primarily mediated through a rich array of bioactive molecules and extracellular vesicles (EVs), capable of traversing the blood‐brain barrier.Intriguing research work underscores the therapeutic potential of human platelet lysates (HPL) in neurodegenerative conditions such as Alzheimer’s disease (AD). Platelets contain numerous neurotrophic factors (including BDNF, PDGF, or TGF‐β), cytokines (including PF4 and CCL5), as well as antioxidants (GPX, catalase) and anti‐inflammatory molecules which are instrumental in neuronal survival, repair, and regeneration. The administration of HPL has demonstrated beneficial effects in preclinical models of AD, Parkinson’s disease, traumatic brain injury, and amyotropic lateral sclerosis indicating its potential as a novel, pragmatic, and accessible therapeutic strategy.This presentation highlights the mechanisms underlying platelet‐brain interactions, focusing on how platelet‐derived bioactive molecules and EVs contribute to neuroprotection, anti‐inflammation, and neurorestoration. We will discuss the implications of these findings in developing new therapeutic approaches for AD and other neurodegenerative diseases, emphasizing the translational potential of platelet lysates in clinical settings. The safety, quality, and regulatory considerations for clinical application of HPL will also be addressed, highlighting the need for further research in this promising field.
Efficacy and acceptability of atypical antipsychotics for behavioral and psychological symptoms of dementia: a systematic review and network meta‐analysis
Authors: Lyu Wenqi , Kuang Weihong 
Published: January 2025

AbstractBackgroundBehavioral and psychological symptoms of dementia (BPSD) are highly prevalent in people living with dementia. Atypical antipsychotics (AAPs) are commonly used to treat BPSD, but their comparative efficacy and acceptability are unknown.MethodsThis study was conducted following the guidelines of the Preferred Reporting Items for Systematic Review and Meta‐Analysis (PRISMA). Stata/SE (version 15.1) in a frequentist framework was used for the data analysis. The standard mean difference (SMD) was used to pool the fixed effect of continuous outcomes. We calculated odds ratios (ORs) with corresponding 95% credible intervals (CI) for the categorical variable. Relative treatment rankings were reported with mean ranks and the surface under the cumulative ranking curve.ResultsTwenty RCTs with a total of 6374 individuals containing 5 types of AAPs (quetiapine, olanzapine, risperidone, brexpiprazole, and aripiprazole) with intervention lengths ranging from 6 weeks to 36 weeks were included in this NMA. For the efficacy outcome, compared with the placebo, brexpiprazole (SMD = ‐1.77, 95% CI ‐2.80 to ‐0.74) was more efficacious, and brexpiprazole was better than quetiapine, olanzapine, and aripiprazole. Regarding acceptability, only aripiprazole (OR = 0.72, 95% CI 0.54 to 0.96) was better than the placebo, and the brexpiprazole (OR = 1.65, 95% CI 1.01 to 2.70) was worse than aripiprazole. In terms of tolerability, olanzapine was worse than placebo (OR = 6.02, 95% CI 2.87 to 12.66), risperidone (OR = 3.67, 95% CI 1.66 to 8.11), and quetiapine (OR = 3.71, 95% CI 1.46 to 9.42), while aripiprazole was better than olanzapine (OR = 0.25, 95% CI 0.08 to 0.78).ConclusionBrexpiprazole has shown great potential efficacy in the treatment of BPSD, with the highest acceptability of aripiprazole and the worst tolerability of olanzapine. The results of this study may be used to guide decision‐making.
Frontotemporal Degeneration (FTD): Community Perspectives on Clinical Trials
Authors: Dodge Shana G , Milliard Carrie , Dacks Penny A. 
Published: January 2025

AbstractBackgroundFrontotemporal degeneration (FTD) is a complex, heterogeneous group of fatal adult‐onset disorders which lead to progressive dysfunction in behavior, motor symptoms, language, and/or cognition. While advances in research are cause for optimism, trials are hindered by the availability of participants. As FTD clinical trials typically require co‐participation of a study partner, care partner perspectives on research are critical to understanding how to support recruitment and retention.MethodAn anonymized online survey queried aspects of the lived experience of FTD from the perspectives of people diagnosed, care partners, and biological family members from the United States, Canada, and the UK. The survey was circulated by the Association for Frontotemporal Degeneration (AFTD), the FTD Disorders Registry (FTDDR), and partner non‐profits, with 1800 complete responses, of which 1246 were from current or former care partners.ResultThe percentage of care partners willing or very willing to participate in a clinical trial was highest amongst those caring for individuals at mild or moderate stages of disease (70% and 66%, respectively), though 49% of care partners were willing or very willing even at profound stages. Of those willing to participate, the diagnosed person’s reported willingness to answer detailed questions differed between those at earlier stages and those who were more progressed while lumbar punctures were the study procedure reported as least likely for the person diagnosed to be willing to undergo, at any stage of disease. Factors that increase willingness to participate included trial decentralization.ConclusionFTD care partners are integral stakeholders in successful clinical trials. Their perceptions of clinical trials and openness to facilitating enrollment of the person diagnosed are moderated by factors such as disease severity and trial burden. Researchers must ensure the perspectives of people impacted by FTD are accounted for in trial design.
Optimal cut‐off scores for mild cognitive impairment and dementia of the Spanish version of the Montreal Cognitive Assessment in Costa Rican older adults
Authors: Boza Carolina , Ulate‐Aguilar Jose Pablo , Rojas‐Salazar Shirley , Román Norbel , Masurkar Arjun V. 
Published: January 2025

AbstractBackgroundAlzheimer’s disease and related dementias (AD/ADRD) burden in Costa Rica is expected to become one of the highest in the region. Early detection will help optimize resources and improve primary care interventions. The Montreal Cognitive Assessment (MoCA) has shown good sensitivity for detection of mild cognitive impairment (MCI), but specificity varies depending on the population. This motivates the analysis of different cut‐offs to minimize false‐positive classifications in a Costa Rican sample for its use in clinical settings.MethodsData was analyzed from 516 memory clinic outpatients (148 cognitively normal, 260 MCI, 108 mild dementia; mean age 66.3 ± 10.8 years) who underwent complete neurological and neuropsychological assessment and were diagnosed by consensus. Optimal MoCA cut‐off scores were identified using the Youden’s Index, balanced cut‐offs, and specificity scores.ResultsOverall, a cut‐off score of ≥23 showed better accuracy to distinguish between NC and MCI (sensitivity 73%, specificity 83%). When analyzed by educational levels, cut‐off scores of ≥21 showed better accuracy for ≤6 years (sensitivity 80%, specificity 76%), ≥23 for 7‐12 years (sensitivity 86%, specificity 76%) and ≥24 for ≥12 years (sensitivity 70%, specificity 85%). For distinguishing MCI from mild dementia, the optimal overall cut‐off score was ≥15 (sensitivity 65%, specificity 85%). When stratified by years of education, cut‐off scores of ≥14 showed better accuracy for ≤6 years (sensitivity 70%, specificity 88%), ≥15 for 7‐12 years (sensitivity 79%, specificity 95%) and ≥17 for ≥12 years (sensitivity 67%, specificity 93%).ConclusionsA MoCA cut‐off score of ≥23 in Costa Rican population showed better diagnostic accuracy and may reduce the false positive rate. Our findings may be helpful for primary care clinical settings and further referral criteria.KeywordsMoCA, Montreal Cognitive Assessment
A novel digital paradigm of orientation is associated with amyloid and tau among cognitively unimpaired individuals
Authors: Dubbelman Mark A. , Elias Uri , Palmer Phebe , Dafni‐Merom Amnon , Amariglio Rebecca E , Papp Kathryn V , Udeogu Onyinye , Wang Sharon , Arzy Shahar , Marshall Gad A 
Published: January 2025

AbstractBackgroundOrientation in time, space, and person is often impaired in Alzheimer’s disease dementia. Subtle changes in orientation may occur in prodromal and preclinical disease stages. Here we aim to assess the cross‐sectional association between individuals’ orientation to their own world, as measured with a novel AI‐based paradigm, and Alzheimer’s disease biomarkers (amyloid and tau) in cognitively unimpaired older adults.MethodsUsing an automated chatbot, 51 participants (74.2 ± 5.3 years, 57% female) provided details about personal memories and relationships (orientation in person), as well as recognition of dates of historical events (orientation in time) and geographical locations (orientation in space). Then, they answered ten questions for each of the three domains of orientation. Orientation accuracy was defined as the proportion of correct responses to these questions divided by the time taken to respond to all questions for each domain separately. All participants underwent Pittsburgh compound‐B (amyloid) and flortaucipir (tau) positron emission tomography (PET) scans. We analyzed the relationship between performance on the three orientation domains and the following PET regions of interests: global cortical amyloid and neocortical, medial temporal, retrosplenial, and precuneus tau. All models are adjusted for age, sex, and education.ResultsHigher global amyloid burden was significantly associated with worse orientation in space, while interactions between amyloid and medial temporal and retrosplenial tau were significantly associated with orientation in time (see Table 1). Orientation in person was not associated with amyloid or tau. Figure 1 displays the relationship between orientation accuracy and amyloid for tertiles of medial temporal and retrosplenial tau.ConclusionWe found associations between orientation in space and time, but not person, and amyloid and tau, even in this small sample of individuals who were cognitively unimpaired, in agreement with previous work, which has shown that orientation in space and time deteriorates earlier in the course of Alzheimer’s disease than orientation in person. These results suggest disorientation to be a core cognitive impairment along the Alzheimer’s disease continuum and may infer a role for routine assessment of orientation, assessed using a personally tailored digital tool, in early diagnosis of Alzheimer’s disease.
Correlation Between QEEG Patterns and Neuropsychological Profile in Patients with Cognitive Impairment from the Colombian Caribbean
Authors: Preciado Jose Hernandez , Vargas Alex Dominguez , Torres Wanda , Pianneta Yesenia , Medina Mauricio , Sinisterra Marybel , Vargas José 
Published: January 2025

AbstractBackgroundQuantitative Electroencephalography (qEEG) plays a pivotal role in the assessment and categorization of cognitive impairment (CI). The integration of qEEG markers with neuropsychological test scores can predict rapid cognitive decline in neurodegenerative diseases. The aim of this study was to correlate qEEG findings with the neuropsychological profile in patients with CI from the Colombian Caribbean.MethodsA cross‐sectional study. Patients with CI (n = 151) from the northern coast of the Colombian Caribbean region were included. Cognitive function was assessed using qEEG and it was categorized as follows: low beta activity (mild CI) (n = 6), frontal slowing (moderate CI) (n = 137), and alterations in alpha activity (severe CI) (n = 8). A cuantitative and normative EEG (Z‐score) was performed using the international 10‐20 system assembly, a 36 channel EEG amplifier and normative database software‐Neurovirtual were used. Neuropsychological profiling was assessed using the following tests: Hopkins Verbal Learning Test‐Revised (HVLT‐R), Clue Recall, Delayed Recall, Memory Complaint Scale (MCS), Trail Making Test Part A and B (TMT‐A/B), Symbol‐Digit test, Lawton & Brody, Yesavage, and Montreal Cognitive Assessment (MoCA). Principal component analysis was used to assess relationships between qEEG categories and the neuropsychological profile (Figure 1).ResultsPatients with alterations in alpha activity exhibited significantly lower scores on the Lawton & Brody test (p = 0.02) and MoCA (p = 0.04) and higher scores on the Yesavage test (p = 0.04). Significant positive correlations were observed between HLVT‐R and Clue recall tests (Spearman r = 0.83, p<0.001), as well as between the MOCA and Lawton & Brody tests (Spearman r = 0.74, p>0.001). In contrast, significant negative correlations were found between the Yesavage and Lawton & Brody tests (Spearman r = ‐0.45, p = 0.008).ConclusionsIn this study, patients with alterations in alpha activity were correlated with lower cognitive performance and emotional impairment. This study underscores the importance of qEEG in conjunction with the neuropsychological profile in evaluating cognitive impairment, emphasizing its utility in diagnostic and therapeutic interventions in cognitive health planning.